---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-184748"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2023-07-10T23:59:59+00:00"
generated_at: "2026-06-13T10:36:44.094528+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fulcrum licenses CAMP4's Diamond Blackfan Anemia program for up to $70M in milestones plus royalties

## Summary
- Exclusive worldwide license to CAMP4's DBA program, including small molecule compounds and patent rights.
- Undisclosed upfront payment; up to $35M in development/regulatory milestones and $35M in sales milestones.
- Royalties on net sales: mid-single to low-double digit, subject to reductions for patent loss or generics.
- Fulcrum responsible for all development and regulatory costs; CAMP4 may terminate for non-payment or patent challenges.
- License expires per product/country upon later of patent expiry, regulatory exclusivity end, or 10 years after first sale.

## SEC filing metadata
- accession: 0001193125-23-184748
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2023-07-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312523184748/0001193125-23-184748-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312523184748/d443448d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-184748
- JSON: https://secwatch.observer/filing/0001193125-23-184748.json
- Plain text: https://secwatch.observer/filing/0001193125-23-184748.txt

## Key facts
- Material Agreements
  Fulcrum Therapeutics, Inc. entered into License Agreement with CAMP4 Therapeutics Corporation (effective 2023-07-05).
  - Action: entry
  - Agreement: license
  - Counterparty: CAMP4 Therapeutics Corporation
  - Effective: 2023-07-05
  source text: On July 5, 2023, Fulcrum Therapeutics, Inc., or Fulcrum, entered into a license agreement with CAMP4 Therapeutics Corporation, or CAMP4
  evidence_url: https://www.sec.gov/Archives/edgar/data/1680581/000119312523184748/0001193125-23-184748-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.